Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-5280
- Development stage
- Phase 1
- Lead developer
- Rise Therapeutics
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
R-5280 is an orally administered live biotherapeutic product (LBP) developed by Rise Therapeutics for the treatment of newly diagnosed Type 1 Diabetes (T1D). The drug consists of an engineered strain of *Lactococcus lactis* designed to deliver specific immunomodulatory signals directly to the gut-associated lymphoid tissue (GALT). By engaging the intestinal immune system, R-5280 aims to induce the expansion of antigen-specific regulatory T cells (Tregs) that can suppress the autoimmune destruction of pancreatic beta cells. This approach is intended to preserve endogenous insulin production and mitigate the progression of T1D in patients with recent-onset disease.
Beyond the preview
Go deeper on R-5280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-5280.